Are you Dr. Chyung?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 14 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Cox-201, Allergy Clinic, Massachusetts General Hospital
Boston, MA 02114Phone+1 617-726-3850- Is this information wrong?
Summary
- Dr. Yung Chyung, MD is an allergist/immunologist in Boston, Massachusetts.
Education & Training
Massachusetts General HospitalFellowship, Allergy and Immunology, 2006 - 2008
Harvard Medical SchoolClass of 2003
Clinical Trials
- Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema Start of enrollment: 2010 Feb 01
Publications & Presentations
PubMed
- 19 citationsA Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscula...Doreen Barrett, Sanela Bilic, Yung Chyung, Shaun M. Cote, Ryan Iarrobino, Katherine Kacena, Ashish Kalra, Long Kimberly, George Nomikos, Amy Place, James Gordon Still,...> ;Advances in Therapy. 2021 May 8
- 103 citationsInhibiting plasma kallikrein for hereditary angioedema prophylaxisAleena Banerji, Paula J. Busse, Mustafa Shennak, William R. Lumry, Mark Davis-Lorton, Henry J. Wedner, Joshua J. Jacobs, James W. Baker, Jonathan A. Bernstein, Richard...> ;The New England Journal of Medicine. 2017 Feb 17
- 28 citationsCharacterization of Anaphylaxis After Ecallantide Treatment of Hereditary Angioedema AttacksTimothy J. Craig, H. Henry Li, Marc A. Riedl, Jonathan A. Bernstein, William R. Lumry, Andrew J. MacGinnitie, Leslie E. Stolz, Joseph C. Biedenkapp, Yung Chyung> ;The Journal of Allergy and Clinical Immunology. in Practice. 2015 Mar 1
- Join now to see all
Press Mentions
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)December 1st, 2021- Scholar Rock Presents Data from Part a of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination WithNovember 12th, 2021
- Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual CongressSeptember 23rd, 2021
- Join now to see all
